Physician profile
Marjorie Levitan
NPI 1609025949
$921.09
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $502 · 2021: $76.39 · 2022: $12.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $549.93 | 2019-2021 | |
| Allergan, INC. | $177.63 | 2020 | |
| Abbvie INC. | $45.43 | 2021 | |
| Amarin Pharma, INC. | $43.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $23.79 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.76 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.76 | 2020 | |
| Lilly USA, LLC | $13.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.